Additional File 4. Comparison of plasma immune checkpoint proteins between females who spontaneously cleared HCV (SC group) versus controls (C group).

| Marker | Un-adjusted | | | Adjusted | | |
	AMR (95%CI)	*p*-value	*q*-value	aAMR (95%CI)	*p*-value	*q*-value
BTLA	1.31 (1.02–1.67)	**0.041**	0.263	1.24 (0.97–1.57)	0.098	0.211
CD137(4-1BB)	1.40 (1.07–1.83)	**0.020**	0.263	1.38 (1.08–1.76)	**0.016**	0.121
CD152(CTLA4)	1.56 (1.02–2.39)	**0.048**	0.263	1.56 (1.00–2.42)	0.058	0.163
CD27	1.30 (0.92–1.83)	0.150	0.263	1.27 (0.85–1.90)	0.254	0.374
CD28	1.35 (0.94–1.94)	0.115	0.263	1.24 (0.87–1.78)	0.241	0.374
CD80	1.44 (1.01–2.07)	0.055	0.263	1.46 (1.01–2.11)	0.054	0.163
GITR	1.41 (1.00–1.98)	0.059	0.263	1.53 (1.11–2.12)	**0.017**	0.121
HVEM	1.31 (0.99–1.73)	0.071	0.263	1.44 (1.08–1.91)	**0.019**	0.121
IDO	1.34 (0.96–1.88)	0.101	0.263	1.23 (0.89–1.71)	0.228	0.374
LAG-3	1.33 (0.92–1.93)	0.139	0.263	1.46 (1.01–2.09)	0.053	0.163
PD-1	1.32 (0.95–1.84)	0.110	0.263	1.35 (0.97–1.89)	0.085	0.199
PD-L1	1.20 (0.87–1.65)	0.287	0.383	1.24 (0.90–1.70)	0.195	0.374
PD-L2	2.10 (1.58–2.79)	**<0.001**	**0.001**	2.19 (1.65–2.91)	**<0.001**	**<0.001**
TIM-3	1.32 (0.97–1.8*0*)	0.083	0.263	1.21 (0.88–1.66)	0.250	0.374
Arginase	0.79 (0.61–1.02)	0.086	0.263	0.72 (0.55–0.94)	**0.022**	0.121
E-Cadherin	1.12 (0.70–1.79)	0.635	0.729	0.95 (0.58–1.57)	0.857	0.857
MICA	0.93 (0.67–1.29)	0.651	0.729	0.86 (0.63–1.16)	0.336	0.449
MICB	1.00 (0.75–1.33)	0.997	0.997	1.06 (0.80–1.41)	0.701	0.727
NT5E(CD73)	1.22 (0.90–1.65)	0.212	0.297	1.19 (0.87–1.63)	0.283	0.397
Nectin-2(CD112)	1.43 (0.92–2.24)	0.128	0.263	1.53 (0.96–2.42)	0.083	0.199
PVR(CD155)	1.06 (0.78–1.43)	0.719	0.774	0.94 (0.68–1.29)	0.685	0.727
Perforin	1.40 (0.89–2.21)	0.154	0.263	1.17 (0.73–1.89)	0.519	0.609
Siglec-7	1.26 (0.92–1.73)	0.160	0.263	1.22 (0.88–1.70)	0.236	0.374
Siglec-9	0.98 (0.68–1.41)	0.918	0.952	0.86 (0.58–1.26)	0.448	0.570
Tactile(CD96)	0.76 (0.50–1.15)	0.198	0.292	0.64 (0.41–0.99)	0.058	0.163
ULBP-1	0.88 (0.56–1.36)	0.560	0.681	0.86 (0.54–1.36)	0.522	0.609
ULBP-3	0.79 (0.56–1.11)	0.186	0.289	0.70 (0.50–0.96)	**0.038**	0.163
ULBP-4	1.06 (0.89–1.25)	0.546	0.681	1.06 (0.88–1.26)	0.556	0.622

Statistics: Data were calculated by Generalized Linear Models (GLM) with a gamma distribution (log-link). Multivariable models were adjusted by age, IL28 genotype, and AST, previously selected by a stepwise method (forward) (see **Results Section**). The q-values represent p-values corrected for multiple testing using the False Discovery Rate (FDR). Significant differences are shown in bold.

Abbreviations: AMR, arithmetic mean ratio; aAMR, adjusted AMR; 95%CI, 95% of confidence interval; p, level of significance; q, corrected level of significance; BTLA, B and T lymphocyte attenuator; CD, cluster of differentiation; GITR, glucocorticoid-induced TNFR-related; HVEM, herpesvirus entry mediator; IDO, indoleamine 2,3-dioxygenase; LAG-3, lymphocyte activation gene-3; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; MICA, MHC class I chain-related gene A; MICB, MHC class I chain-related gene B; NT5E, ecto-5′-nucleotidase; PVR, poliovirus receptor; Siglec, sialic acid-binding immunoglobulin-type lectin; ULBP, human ligand for binding protein.